Poirier Michael S. 4

4 · Qualigen Therapeutics, Inc. · Filed May 27, 2020

Form 4

Period: 2020-05-22

DirectorChairman, President & CEO.

Transactions

Other
Warrant (Right to Buy)
2020-05-22+22,142→ 22,142 total
Exercise: $2.07From: 2020-05-22Exp: 2024-01-31→ Common Stock (22,142 underlying)
Other
Warrant (Right to Buy)
2020-05-22+14,437→ 14,437 total
Exercise: $2.54From: 2020-05-22Exp: 2026-09-22→ Common Stock (14,437 underlying)
Other
Warrant (Right to Buy)
2020-05-22+22,142→ 22,142 total
Exercise: $2.54From: 2020-05-22Exp: 2025-03-02→ Common Stock (22,142 underlying)
Other
Common Stock
2020-05-22+169,192→ 169,192 total
Other
Warrant (Right to Buy)
2020-05-22+29,847→ 29,847 total
Exercise: $2.07From: 2020-05-22Exp: 2024-08-02→ Common Stock (29,847 underlying)

Footnotes (3)

[F1]On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. ("Qualigen") was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the "Merger"). Pursuant to and effective as of the closing of the Merger (the "Closing"), the Reporting Person became an officer and director of the Issuer.
[F2]Immediately prior to the Closing, the Reporting Person was a stockholder of Qualigen. Pursuant to the Merger, the shares of Qualigen common stock previously held by the Reporting Person were converted into 169,192 shares of common stock of the Issuer.
[F3]Pursuant to the Merger, Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.

Documents

1 file